Brian Schwartz Selected Research

Biomarkers (Surrogate Marker)

1/2018	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
4/2017	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
11/2009	The Toronto prehospital hypertonic resuscitation-head injury and multi organ dysfunction trial (TOPHR HIT)--methods and data collection tools.
4/2007	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
3/2007	Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
9/2006	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian Schwartz Research Topics

Disease

31	Neoplasms (Cancer) 10/2020 - 02/2005
8	Hepatocellular Carcinoma (Hepatoma) 02/2018 - 09/2006
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 01/2011
7	Neutropenia 01/2018 - 01/2006
7	Renal Cell Carcinoma (Grawitz Tumor) 12/2012 - 06/2006
7	Fatigue 04/2011 - 01/2006
5	Proteus Syndrome 01/2020 - 01/2017
5	Diarrhea 07/2016 - 09/2006
4	Disease Progression 01/2018 - 01/2007
4	Exanthema (Rash) 07/2016 - 06/2006
3	Cholangiocarcinoma 01/2019 - 01/2016
3	Wounds and Injuries (Trauma) 01/2019 - 04/2002
3	Fibrosis (Cirrhosis) 02/2018 - 01/2013
3	Colorectal Neoplasms (Colorectal Cancer) 07/2016 - 09/2005
3	Nausea 07/2016 - 03/2007
3	Human Influenza (Influenza) 05/2016 - 10/2012
3	Melanoma (Melanoma, Malignant) 02/2015 - 03/2007
3	ST Elevation Myocardial Infarction 04/2013 - 01/2008
3	Hypertension (High Blood Pressure) 11/2008 - 08/2004
2	Hematologic Neoplasms (Hematological Malignancy) 10/2020 - 10/2018
2	Carcinogenesis 10/2020 - 01/2020
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2020 - 01/2020
2	Leukemia 10/2020 - 01/2015
2	Social Phobia 01/2020 - 12/2019
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 10/2018
2	Poisoning 01/2020 - 10/2018
2	Necrosis 10/2018 - 09/2016
2	Infections 01/2018 - 05/2016
2	Vomiting 12/2011 - 04/2011
2	Thrombocytopenia (Thrombopenia) 12/2011 - 01/2006
2	Craniocerebral Trauma (Head Injury) 08/2011 - 11/2009
2	Kidney Neoplasms (Kidney Cancer) 06/2007 - 10/2006
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 09/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 07/2021
1	Atrial Fibrillation 01/2021
1	Heart Failure 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	COVID-19 01/2021
1	Carcinoma (Carcinomatosis) 01/2019
1	Rare Diseases (Rare Disease) 01/2019
1	Symptom Flare Up 01/2019
1	Neonatal Abstinence Syndrome 10/2018
1	Liver Failure 01/2018
1	Ascites 01/2018
1	Pain (Aches) 01/2018
1	Febrile Neutropenia 01/2018
1	Acute Coronary Syndrome 01/2018
1	Abdominal Pain (Pain, Abdominal) 01/2018
1	Cutaneous Leishmaniasis 01/2018
1	Sepsis (Septicemia) 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018

Drug/Important Bio-Agent (IBA)

15	ARQ 197IBA 01/2019 - 01/2011
15	Sorafenib (BAY 43-9006)FDA Link 02/2018 - 02/2005
9	MiransertibIBA 01/2020 - 01/2015
9	Pharmaceutical PreparationsIBA 01/2017 - 03/2002
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 01/2011
6	Phosphotransferases (Kinase)IBA 10/2020 - 09/2005
6	Biomarkers (Surrogate Marker)IBA 01/2018 - 09/2006
3	ibrutinibIBA 10/2020 - 10/2018
3	Agammaglobulinaemia Tyrosine KinaseIBA 10/2020 - 10/2018
3	Tyrosine Kinase InhibitorsIBA 10/2020 - 08/2011
3	derazantinibIBA 01/2019 - 01/2016
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2011 - 02/2005
3	raf KinasesIBA 09/2006 - 02/2005
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 12/2012
2	Opioid Analgesics (Opioids)IBA 01/2020 - 10/2018
2	IntegrinsIBA 01/2017 - 04/2002
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2016 - 09/2005
2	Irinotecan (Camptosar)FDA LinkGeneric 07/2016 - 01/2011
2	Cetuximab (Erbitux)FDA Link 07/2016 - 01/2011
2	Adenosine Triphosphate (ATP)IBA 01/2016 - 01/2011
2	methionylmethionine (Met-Met)IBA 08/2011 - 01/2011
2	Saline SolutionIBA 08/2011 - 11/2009
2	Dextrans (Dextran)FDA Link 08/2011 - 11/2009
2	Gemcitabine FDA Link 01/2011 - 01/2006
2	Amlodipine (Norvasc)FDA LinkGeneric 11/2008 - 08/2004
2	tyrosine receptor (receptor, tyrosine)IBA 04/2007 - 09/2006
1	Imatinib Mesylate (Gleevec)FDA Link 07/2021
1	Carvedilol (Coreg)FDA LinkGeneric 01/2021
1	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2021
1	RNA (Ribonucleic Acid)IBA 10/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2020
1	ARQ531IBA 10/2020
1	Tyrosine (L-Tyrosine)FDA Link 10/2020
1	Syk KinaseIBA 01/2020
1	src-Family KinasesIBA 01/2020
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 01/2019
1	Explosive Agents (Explosives)IBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	beta-lapachoneIBA 10/2018
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 02/2018
1	Aligeron (AS 2)IBA 01/2017

Therapy/Procedure

23	Therapeutics 09/2021 - 06/2006
4	Percutaneous Coronary Intervention 04/2013 - 01/2008
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2018
2	Resuscitation 08/2011 - 11/2009
1	Precision Medicine 01/2019
1	Arthroplasty 01/2018
1	Arthrodesis 01/2018
1	Investigational Therapies (Experimental Therapy) 04/2017